drugset / Trial / NCT02021669

Omega-3 for Depression and Other Cardiac Risk Factors - 2

NCT02021669

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for major depression in patients with coronary heart disease (CHD).

Timeline

Start
2014-05-14
Primary completion
2018-09-13
Completion
2018-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Eicosapentaenoic acid Small molecule 2 g
Background Sertraline Small molecule 50 mg

Indications